

Online Table 1 | Studies in ovarian cancer of molecular markers of drug resistance or prognosis

	<i>In vitro</i>		Number of clinical studies with a correlation* with:						
	Platinum	Taxane	Resistance Total number	Positive	No correlation	Prognosis Negative	Positive	No correlation	Negative
Drug efflux									
MDR	(-) ¹	(+) ⁵	23	5 (REF. 8)	11 (REF. 11)		5 (REF. 13)	11 (REF. 11)	
MRP	(-) ^{2,3}	(+) ⁶	9	2 (REF. 9)	4 (REF. 11)		1 (REF. 9)	4 (REF. 11)	
LRP	(+) ³	(+) ⁷	8	1 (REF. 10)	4 (REF. 12)		2 (REF. 10)	4 (REF. 12)	
ATP7A/B	(+) ⁴		1				1 (REF. 14)		
Drug inactivation									
MT	(-) ¹⁵		3		2 (REF. 21)			2 (REF. 26)	
GGCS	(+) ¹⁶		1	1 (REF. 19)					
GSH	(+) ¹⁷		4	1 (REF. 20)	1 (REF. 22)			2 (REF. 26)	
GST	(+) ¹⁸		19	7 (REF. 12)	8 (REF. 23)	1 (REF. 24)	9 (REF. 25)	4 (REF. 23)	1 (REF. 12)
Target modification									
β-tubulin isotypes		(+) ²⁷	2	1 (REF. 29)	1 (REF. 27)				
β-tubulin mutations		(+) ²⁸	1		1 (REF. 30)				
DNA repair									
XPA	(+) ³¹		1	1 (REF. 33)					
ERCC1	(+) ³¹		1	1 (REF. 34)					
DNA-polymerase	(+) ³²								
Damage signalling									
ATM									
CHK2									
MLH1	(+) ³⁵ , (-) ³⁶		2		1 (REF. 38)	1 (REF. 37)		1 (REF. 38)	
MSH2	(-) ³⁷		3		2 (REF. 38)			1 (REF. 38)	1 (REF. 39)
Cell-cycle control									
MYC			8	1 (REF. 50)	4 (REF. 53)		1 (REF. 60)	7 (REF. 53)	
JUN	(+) ⁴⁰		1		1 (REF. 9)			1 (REF. 9)	
FOS	(+) ⁴¹								
ARF									
MDM2	(+) ⁴²	(+) ⁴²	5		3 (REF. 54)			4 (REF. 61)	1 (REF. 66)
p53	(+) ^{43,44} , (-) ⁴⁵	(-) ^{47,48}	>30	REFS 51,52	REF. 55		REF. 54	REFS 23,62,63	
INK4A		(-) ⁴⁹	6		2 (REF. 56)	1 (REF. 58)	1 (REF. 56)	4 (REF. 64)	1 (REF. 58)
Cyclins	(+) ⁴⁶	(+) ⁴⁶	ND						
RB			3		1 (REF. 56)		1 (REF. 56)	1 (REF. 65)	1 (REF. 67)
WAF1			13		5 (REF. 57)			6 (REF. 57)	7 (REF. 68)
KIP1			12		1 (REF. 57)	1 (REF. 59)		4 (REF. 57)	8 (REF. 59)
Growth-factor signalling									
ERBB1	(+) ^{69,70} , (-) ⁷¹	(+) ⁶⁹	>30 (including ERBB2)	REF. 83	REF. 85	REF. 53	REF. 83	REF. 85	
ERBB2	(+) ⁷²			REF. 83	REF. 86		REF. 87	REF. 60	
RAS	(-) ⁷³	(+) ⁷⁷	9	1 (REF. 84)	1 (REF. 83)		3 (REF. 60)	5 (REF. 83)	
RAF		(+) ⁷⁸							
MEK/ERK	(+) ^{74,75}	(+) ⁷⁹							
PTEN/PDK/PI3K	(+) ⁷⁶	(+) ⁸⁰							
AKT	(+) ⁷⁶	(+) ^{81,82}							
Apoptosis									
BCL2	(+) ⁴⁴ , (-) ⁸⁸	(+) ⁹¹	22	2 (REF. 94)	5 (REF. 23)		2 (REF. 54)	14 (REF. 23)	5 (REF. 97)
BCL-X _L	(+) ⁴⁴ , (-) ⁸⁸	(+) ⁹¹							
BAD	(+) ⁸⁹	(+) ⁹²							
BAK									
BAX	(+) ^{46,43}	(+) ⁹³	11		2 (REF. 95)		1 (REF. 97)	5 (REF. 99)	5 (REF. 95)
XIAP	(+) ⁹⁰								
Survivin				3			3 (REF. 98)		
XIST				1			1 (REF. 96)		

In vitro studies: (-) denotes studies showing no association of the molecular marker with resistance; (+) denotes studies supporting a role for the molecular marker in chemoresistance. * The correlation is between expression of the marker and chemoresistance or prognosis. Positive, increased marker correlates with resistance/poor prognosis; negative, increased marker correlates with chemosensitivity/good prognosis. GGCS, gamma-glutamyl cysteine synthetase; GSH, glutathione; GST, glutathione-S-transferase; LRP, lung-resistance protein; MDR, multidrug-resistance; MRP, multidrug-resistance protein; MT, metallothionein; ND, not determined.

1. Kuppen, P. J. *et al.* cis-diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines. *Cancer Res.* **48**, 3355–3359 (1988).
2. Sharp, S. Y., Smith, V., Hobbs, S. & Kelland, L.R. Lack of role for MRP1 in platinum drug resistance in human ovarian cancer cell lines. *Br. J. Cancer* **78**, 175–180 (1998).
3. Chen, J., Yang, R. & Liu, F. [Establishment of cisplatin-induced multidrug resistant human epithelial ovarian cancer cell line 3AO/cDDP and its expressions of multidrug resistance proteins]. *Zhonghua Fu Chan Ke Za Zhi* **35**, 617–620 (2000).
4. Katano, K. *et al.* Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. *Cancer Res.* **62**, 6559–6565 (2002).
5. Ling, V. Charles F. Kettering Prize. P-glycoprotein and resistance to anticancer drugs. *Cancer* **69**, 2603–2609 (1992).
6. Nooter, K. & Stoter, G. Molecular mechanisms of multidrug resistance in cancer chemotherapy. *Pathol. Res. Pract.* **192**, 768–780 (1996).
7. Laurencot, C. M., Scheffer, G. L., Scheper, R. J. & Shoemaker, R. H. Increased LRP mRNA expression is associated with the MDR phenotype in intrinsically resistant human cancer cell lines. *Int. J. Cancer* **72**, 1021–1026 (1997).
8. Holzmayer, T. A., Hilsenbeck, S., Von Hoff, D. D. & Roninson, I. B. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. *J. Natl Cancer Inst.* **84**, 1486–1491 (1992).
9. Yokoyama, Y. *et al.* Significance of multi-drug-resistant proteins in predicting chemotherapy response and prognosis in epithelial ovarian cancer. *J. Obstet. Gynaecol. Res.* **25**, 387–394 (1999).
10. Izquierdo, M. A. *et al.* Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. *J. Natl Cancer Inst.* **87**, 1230–1237 (1995).
11. Arts, H. J. *et al.* Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. *Clin. Cancer Res.* **5**, 2798–2805 (1999).
12. Mayr, D. *et al.* Immunohistochemical analysis of drug resistance-associated proteins in ovarian carcinomas. *Pathol. Res. Pract.* **196**, 469–475 (2000).
13. Schneider, J., Jimenez, E., Marenbach, K., Marx, D. & Meden, H. Co-expression of the MDR1 gene and HSP27 in human ovarian cancer. *Anticancer Res.* **18**, 2967–2971 (1998).
14. Nakayama, K. *et al.* Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP. *Int. J. Cancer* **101**, 488–495 (2002).
15. Schilder, R. J. *et al.* Metallothionein gene expression and resistance to cisplatin in human ovarian cancer. *Int. J. Cancer* **45**, 416–422 (1990).
16. Yao, K. S. *et al.* Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines. *Cancer Res.* **55**, 4367–4374 (1995).
17. Godwin, A. K. *et al.* High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. *Proc. Natl Acad. Sci. USA* **89**, 3070–3074 (1992).
18. Mistry, P., Kelland, L. R., Abel, G., Sidhar, S. & Harrap, K. R. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. *Br. J. Cancer* **64**, 215–220 (1991).
19. Kigawa, J., Minagawa, Y., Cheng, X. & Terakawa, N. Gamma-glutamyl cysteine synthetase up-regulates glutathione and multidrug resistance-associated protein in patients with chemoresistant epithelial ovarian cancer. *Clin. Cancer Res.* **4**, 1737–1741 (1998).
20. Kigawa, J. *et al.* Glutathione concentration may be a useful predictor of response to second-line chemotherapy in patients with ovarian cancer. *Cancer* **82**, 697–702 (1998).
21. Germain, I., Tetu, B., Brisson, J., Mondor, M. & Chérián, M. G. Markers of chemoresistance in ovarian carcinomas: an immunohistochemical study of 86 cases. *Int. J. Gynecol. Pathol.* **15**, 54–62 (1996).
22. Joncourt, F. *et al.* Multiple drug resistance parameter expression in ovarian cancer. *Gynecol. Oncol.* **70**, 176–182 (1998).
23. Silvestrini, R. *et al.* The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol. *Cancer* **82**, 159–167 (1998).
24. Ferrandina, G. *et al.* Glutathione S-transferase activity in epithelial ovarian cancer: association with response to chemotherapy and disease outcome. *Ann. Oncol.* **8**, 343–350 (1997).
25. Satoh, T. *et al.* [An immunohistological study on expression of glutathione S-transferase pi (form) in human ovarian carcinoma]. *Nippon Sanka Fujinka Gakkai Zasshi* **47**, 931–938 (1995).
26. Hengstler, J. G. *et al.* Metallothionein expression in ovarian cancer in relation to histopathological parameters and molecular markers of prognosis. *Int. J. Cancer* **95**, 121–127 (2001).
27. Nicoletti, M. I. *et al.* Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents. *Clin. Cancer Res.* **7**, 2912–2922 (2001).
28. Giannakakou, P. *et al.* Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. *J. Biol. Chem.* **272**, 17118–17125 (1997).
29. Kavalariis, M. *et al.* Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. *J. Clin. Invest.* **100**, 1282–1293 (1997).
30. Sale, S. *et al.* Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers. *Mol. Cancer Ther.* **1**, 215–225 (2002).
31. Ferry, K. V., Hamilton, T. C. & Johnson, S. W. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. *Biochem. Pharmacol.* **60**, 1305–1313 (2000).
32. Masuda, H. *et al.* Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. *Cancer Res.* **48**, 5713–5716 (1988).
33. Dabholkar, M., Vionnet, J., Bostick-Bruton, F., Yu, J. J. & Reed, E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. *J. Clin. Invest.* **94**, 703–708 (1994).
34. Dabholkar, M. *et al.* ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. *J. Natl Cancer Inst.* **84**, 1512–1517 (1992).
35. Drummond, J. T., Anthony, A., Brown, R. & Modrich, P. Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line. *J. Biol. Chem.* **271**, 19645–19648 (1996).
36. Branch, P., Masson, M., Aquilina, G., Bignami, M. & Karran, P. Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells. *Oncogene* **19**, 3138–3145 (2000).
37. Brown, R. *et al.* hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. *Oncogene* **15**, 45–52 (1997).
38. Samimi, G. *et al.* Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. *Clin. Cancer Res.* **6**, 1415–1421 (2000).
39. Geisler, J. P. *et al.* Immunohistochemical staining of the mismatch repair gene, hMSH2, and survival in patients with ovarian carcinoma. *Eur. J. Gynaecol. Oncol.* **21**, 237–240 (2000).
40. Pan, B. *et al.* Reversal of cisplatin resistance in human ovarian cancer cell lines by a c-jun antisense oligodeoxynucleotide (ISIS 10582): evidence for the role of transcription factor overexpression in determining resistant phenotype. *Biochem. Pharmacol.* **63**, 1699–1707 (2002).
41. Scanlon, K. J. *et al.* Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein. *Proc. Natl Acad. Sci. USA* **88**, 10591–10595 (1991).
42. Atencio, I. A. *et al.* Enhanced apoptotic activity of a p53 variant in tumors resistant to wild-type p53 treatment. *Mol. Ther.* **4**, 5–12 (2001).
43. Perego, P. *et al.* Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. *Cancer Res.* **56**, 556–562 (1996).
44. Eliopoulos, A. G. *et al.* The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. *Oncogene* **11**, 1217–1228 (1995).
45. De Feudis, P. *et al.* DDP-induced cytotoxicity is not influenced by p53 in nine human ovarian cancer cell lines with different p53 status. *Br. J. Cancer* **76**, 474–479 (1997).
46. Smith, M. L. & Seo, Y. R. Sensitivity of cyclin E-overexpressing cells to cisplatin/taxol combinations. *Anticancer Res.* **20**, 2537–2539 (2000).
47. Debernardis, D. *et al.* p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. *Cancer Res.* **57**, 870–874 (1997).
48. Vikhanskaya, F. *et al.* Inactivation of p53 in a human ovarian cancer cell line increases the sensitivity to paclitaxel by inducing G2/M arrest and apoptosis. *Exp. Cell Res.* **241**, 96–101 (1998).
49. Kawakami, Y. *et al.* Adenovirus-mediated p16 gene transfer changes the sensitivity to taxanes and Vinca alkaloids of human ovarian cancer cells. *Anticancer Res.* **21**, 2537–2545 (2001).
50. Bauknecht, T., Birmelin, G. & Kommoss, F. Clinical significance of oncogenes and growth factors in ovarian carcinomas. *J. Steroid Biochem. Mol. Biol.* **37**, 855–862 (1990).
51. Calvert, A. H. *et al.* Carboplatin and paclitaxel, alone and in combination: dose escalation, measurement of renal function, and role of the p53 tumor suppressor gene. *Semin. Oncol.* **26**, 90–94 (1999).
52. Sengupta, P. S. *et al.* p53 and related proteins in epithelial ovarian cancer. *Eur. J. Cancer* **36**, 2317–2328 (2000).
53. Kohler, M., Janz, I., Wintzer, H. O., Wagner, E. & Bauknecht, T. The expression of EGF receptors, EGF-like factors and c-myc in ovarian and cervical carcinomas and their potential clinical significance. *Anticancer Res.* **9**, 1537–1547 (1989).
54. Baekelandt, M., Kristensen, G. B., Nesland, J. M., Trope, C. G. & Holm, R. Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer. *J. Clin. Oncol.* **17**, 2061 (1999).
55. Smith-Sorensen, B. *et al.* Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status. *Br. J. Cancer* **78**, 375–381 (1998).
56. Kusume, T. *et al.* The p16-cyclin D1/CDK4-pRb pathway and clinical outcome in epithelial ovarian cancer. *Clin. Cancer Res.* **5**, 4152–4157 (1999).
57. Baekelandt, M., Holm, R., Trope, C. G., Nesland, J. M. & Kristensen, G. B. Lack of independent prognostic significance of p21 and p27 expression in advanced ovarian cancer: an immunohistochemical study. *Clin. Cancer Res.* **5**, 2848–2853 (1999).
58. Kudoh, K. *et al.* Inactivation of p16/CDKN2 and p15/MTS2 is associated with prognosis and response to chemotherapy in ovarian cancer. *Int. J. Cancer* **99**, 579–582 (2002).
59. Goff, B. A., Paley, P. J., Greer, B. E. & Gown, A. M. Evaluation of chemoresistance markers in women with epithelial ovarian carcinoma. *Gynecol. Oncol.* **81**, 18–24 (2001).
60. Katsaros, D. *et al.* Concurrent abnormal expression of erbB-2, myc and ras genes is associated with poor outcome of ovarian cancer patients. *Anticancer Res.* **15**, 1501–1510 (1995).
61. Skomedal, H. *et al.* TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas. *J. Pathol.* **181**, 158–165 (1997).
62. Thames, H. D., Petersen, C., Petersen, S., Nieder, C. & Baumann, M. Immunohistochemically detected p53 mutations in epithelial tumors and results of treatment with chemotherapy and radiotherapy. A treatment-specific overview of the clinical data. *Strahlenther. Onkol.* **178**, 411–421 (2002).
63. Sheridan, E., Silcocks, P., Smith, J., Hancock, B. W. & Goyns, M. H. P53 mutation in a series of epithelial ovarian cancers from the U.K., and its prognostic significance. *Eur. J. Cancer* **30A**, 1701–1704 (1994).
64. Dong, Y. *et al.* Increased expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product P16INK4A in ovarian cancer is associated with progression and unfavourable prognosis. *Int. J. Cancer* **74**, 57–63 (1997).
65. Peiro, G., Diebold, J. & Lohrs, U. CAS (cellular apoptosis susceptibility) gene expression in ovarian carcinoma: Correlation with 20q13.2 copy number and cyclin D1, p53, and Rb protein expression. *Am. J. Clin. Pathol.* **118**, 922–929 (2002).
66. Tanner, B. *et al.* mdm 2 mRNA expression is associated with survival in ovarian cancer. *Int. J. Cancer* **74**, 438–442 (1997).
67. Dong, Y. *et al.* Reduced expression of retinoblastoma gene product (pRb) and high expression of p53 are associated with poor prognosis in ovarian cancer. *Int. J. Cancer* **74**, 407–415 (1997).
68. Anttila, M. A. *et al.* p21/WAF1 expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer. *Br. J. Cancer* **79**, 1870–1878 (1999).
69. Ciardiello, F. *et al.* Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. *Clin. Cancer Res.* **6**, 2053–2063 (2000).

70. Frankel, A. & Mills, G. B. Peptide and lipid growth factors decrease cis-diamminedichloroplatinum-induced cell death in human ovarian cancer cells. *Clin. Cancer Res.* **2**, 1307–1313 (1996).
71. Christen, R.D. *et al.* Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. *J. Clin. Invest.* **86**, 1632–1640 (1990).
72. Wu, L., Wu, A. & Jiang, K. [Effect of antisense c-erbB2 on biologic behaviour and chemotherapeutic drug sensitivity in human ovarian cancer cells]. *Zhonghua Fu Chan Ke Za Zhi* **31**, 169–172 (1996).
73. Holford, J., Rogers, P. & Kelland, L. R. ras mutation and platinum resistance in human ovarian carcinomas in vitro. *Int. J. Cancer* **77**, 94–100 (1998).
74. Gebauer, G. *et al.* Cisplatin-resistance involves the defective processing of MEKK1 in human ovarian adenocarcinoma 2008/C13 cells. *Int. J. Oncol.* **16**, 321–325 (2000).
75. Cui, W., Yazlovitskaya, E. M., Mayo, M. S., Pelling, J. C. & Persons, D. L. Cisplatin-induced response of c-jun N-terminal kinase 1 and extracellular signal-regulated protein kinases 1 and 2 in a series of cisplatin-resistant ovarian carcinoma cell lines. *Mol. Carcinog.* **29**, 219–228 (2000).
76. Mitsuuchi, Y. *et al.* The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel. *Cancer Res.* **60**, 5390–5394 (2000).
77. Shi, B. *et al.* The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo. *Cancer Chemother. Pharmacol.* **46**, 387–393 (2000).
78. Rasouli-Nia, A., Liu, D., Perdue, S. & Britten, R. A. High Raf-1 kinase activity protects human tumor cells against paclitaxel-induced cytotoxicity. *Clin. Cancer Res.* **4**, 1111–1116 (1998).
79. McDaid, H. M. & Horwitz, S. B. Selective potentiation of paclitaxel (taxol)-induced cell death by mitogen-activated protein kinase inhibition in human cancer cell lines. *Mol. Pharmacol.* **60**, 290–301 (2001).
80. Hu, L., Hofmann, J., Lu, Y., Mills, G.B. & Jaffe, R.B. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in vitro and in vivo ovarian cancer models. *Cancer Res.* **62**, 1087–1092 (2002).
81. Page, C. *et al.* Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. *Anticancer Res.* **20**, 407–416 (2000).
82. Mabuchi, S. *et al.* Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. *J. Biol. Chem.* **277**, 33490–33500 (2002).
83. van Dam, P. A. *et al.* Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma. *J. Clin. Pathol.* **47**, 914–919 (1994).
84. Gadducci, A. *et al.* Immunohistochemical detection of p185 product, p21 product, and proliferating cell nuclear antigen (PCNA) in formalin-fixed, paraffin-embedded tissues from ovarian carcinomas. Preliminary data. *Eur. J. Gynaecol. Oncol.* **15**, 359–368 (1994).
85. Baekelandt, M., Kristensen, G. B., Trope, C. G., Nesland, J. M. & Holm, R. Epidermal growth factor receptor expression has no independent prognostic significance in advanced ovarian cancer. *Anticancer Res.* **19**, 4469–4474 (1999).
86. Goff, B. A., Ries, J. A., Els, L. P., Coltrera, M. D. & Gown, A. M. Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure. *Gynecol. Oncol.* **70**, 378–385 (1998).
87. Hengstler, J. G. *et al.* Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer. *Cancer Res.* **59**, 3206–3214 (1999).
88. Beale, P. J., Rogers, P., Boxall, F., Sharp, S. Y. & Kelland, L. R. BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma. *Br. J. Cancer* **82**, 436–440 (2000).
89. Hayakawa, J. *et al.* Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. *Cancer Res.* **60**, 5988–5994 (2000).
90. Sasaki, H., Sheng, Y., Kotsuji, F. & Tsang, B. K. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. *Cancer Res.* **60**, 5659–5666 (2000).
91. Rogers, P. M. *et al.* Overexpression of BclXL in a human ovarian carcinoma cell line: paradoxical effects on chemosensitivity in vitro versus in vivo. *Int. J. Cancer* **97**, 858–863 (2002).
92. Strobel, T., Tai, Y. T., Korsmeyer, S. & Cannistra, S. A. BAD partly reverses paclitaxel resistance in human ovarian cancer cells. *Oncogene* **17**, 2419–2427 (1998).
93. De Feudis, P. *et al.* Driving p53 response to Bax activation greatly enhances sensitivity to taxol by inducing massive apoptosis. *Neoplasia* **2**, 202–207 (2000).
94. Mano, Y. *et al.* Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer. *Eur. J. Cancer* **35**, 1214–1219 (1999).
95. Baekelandt, M., Holm, R., Nesland, J. M., Trope, C. G. & Kristensen, G. B. Expression of apoptosis-related proteins is an independent determinant of patient prognosis in advanced ovarian cancer. *J. Clin. Oncol.* **18**, 3775–3781 (2000).
96. Huang, K. C. *et al.* Relationship of XIST expression and responses of ovarian cancer to chemotherapy. *Mol. Cancer Ther.* **1**, 769–776 (2002).
97. Marx, D. *et al.* Differential expression of apoptosis associated genes bax and bcl-2 in ovarian cancer. *Anticancer Res.* **17**, 2233–2240 (1997).
98. Sui, L. *et al.* Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors. *Int. J. Oncol.* **21**, 315–320 (2002).
99. Skirnisdottir, I., Seidal, T., Gerdin, E. & Sorbe, B. The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy. *Int. J. Gynecol. Cancer* **12**, 265–276 (2002).